{"id":13252,"date":"2024-05-22T09:47:00","date_gmt":"2024-05-22T09:47:00","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/?post_type=webinar-and-podcast&p=13252"},"modified":"2026-01-23T16:01:28","modified_gmt":"2026-01-23T16:01:28","slug":"the-pursuit-of-mitochondrial-function-for-large-pharma-biotech","status":"publish","type":"webinar-and-podcast","link":"https:\/\/www.sygnaturediscovery.com\/fr\/webinar-and-podcast\/the-pursuit-of-mitochondrial-function-for-large-pharma-biotech\/","title":{"rendered":"The Pursuit of Mitochondrial Function for Large Pharma & Biotech"},"content":{"rendered":"\n

Understanding mitochondrial function is becoming a priority for organisations developing therapies for complex CNS diseases. In this episode, Dr Tatiana Rosenstock explores the key questions large pharma and biotech face when establishing a pharmacological strategy around mitochondrial biology. She explains why mitochondria are such a sensitive indicator of neuronal health and why targeted, mechanistic assessment is essential for meaningful decision-making. <\/p>\n\n\n\n

About Tatiana<\/h3>\n\n\n\n
\n
\n
\"\"\/<\/figure>\n<\/div>\n\n\n\n
\n

Tatiana Rosenstock has had an exceptional career and has made significant contributions to the field of Neuroscience for 20+ years. Her work has focused on topics such as mitochondrial deregulation, transcription deregulation, and autophagy in neurodegenerative diseases, such as Huntington\u2019s Disease, and Amyotrophic Lateral Sclerosis, and Schizophrenia.  <\/p>\n\n\n\n

At Sygnature Discovery, Tatiana is a Principal Scientist overseeing various neuroscience-related projects in different sub-areas such as metabolism (mitochondrial function), biomarkers, microglial function and activation, and neuroplasticity. During this period, she has been working with distinct in-vitro models, named iPSC-derived neurons, primary cortical neurons, Alzheimer`s and Parkinson`s disease fibroblasts, neuroblastomas cell lines, tissue and biofluids from transgenics animal models of Alzheimer`s disease. <\/p>\n<\/div>\n<\/div>\n\n\n\n

What You’ll Learn<\/h2>\n\n\n\n
    \n
  • Why mitochondrial function is now central to CNS drug discovery<\/li>\n\n\n\n
  • The drivers behind increased investment in mitochondrial-focused assays<\/li>\n\n\n\n
  • Key considerations when setting up a pharmacological approach <\/li>\n<\/ul>\n\n\n
    \n\t \n\t\n\t\t\t\t\t\t\n\t\t \t\t\n\t\t\t\t\t\t\t\n\t\t\t
    \n
    \n \n \n\n
    \n